NICE Single Technology Appraisal Guidance 262 – Adalimumab
for the treatment of moderate to severe ulcerative colitis
This NICE guidance was terminated on 25 July
2012 as no evidence submission was provided. The web
reference for related documents is: http://guidance.nice.org.uk/TA262
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (800/12) on
this medication for this indication in July 2012. This stated
that:
adalimumab (Humira ®) is not
recommended for use within NHS Scotland.
Indication under review:
treatment of moderately to severely active ulcerative colitis in
adult patients who have had an inadequate response to conventional
therapy including corticosteroids and 6-mercaptopurine (6-MP) or
azathioprine (AZA), or who are intolerant to or have medical
contraindications for such therapies.
The holder of the marketing authorisation has
not made a submission to SMC regarding this product in this
indication.
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 25 July 2012
